ABSTRACT
Chronic fatigue syndrome (CFS), fibromyalgia, silicone breast implants syndrome (SBIs), COVID and post-COVID syndrome (PCS), sick building syndrome (SBS), post-orthostatic tachycardia syndrome (POTS), autoimmune diseases and autoimmune/inflammatory syndrome induced by adjuvants (ASIA) are frequently accompanied by clinical symptoms characteristic for dysautonomia: severe fatigue, dizziness, fogginess, memory loss, dry mouth and eyes, hearing dysfunction, tachycardia etc. The recent discovery of an imbalance of autoantibodies against G protein-coupled receptors (GPCR) in some autoimmune diseases, post-COVID syndrome, SBIs allowed researchers to assume the novel mechanism in these conditions - autoimmune autonomic nervous system imbalance. In this review, all data published on an imbalance of autoantibodies against GPCR, clinical symptoms and pathogenic mechanisms in CFS, Fibromyalgia, SBIs, COVID and PCS, SBS, POTS, and some autoimmune diseases were analyzed. Possible criteria to diagnose the autoimmune autonomic nervous system imbalance were created.
Subject(s)
Autoimmune Diseases , Breast Implants , COVID-19 , Fatigue Syndrome, Chronic , Fibromyalgia , Primary Dysautonomias , Sick Building Syndrome , Humans , Fatigue Syndrome, Chronic/etiology , Fibromyalgia/etiology , Breast Implants/adverse effects , COVID-19/complications , Autonomic Nervous System , Autoantibodies , Tachycardia , Adjuvants, Immunologic , SiliconesABSTRACT
The Publisher regrets that this article is an accidental duplication of an article that has already been published, https://doi.org/10.1016/j.autrev.2022.103230. The duplicate article has therefore been withdrawn. The full Elsevier Policy on Article Withdrawal can be found at https://www.elsevier.com/about/our-business/policies/article-withdrawal.
ABSTRACT
The modern checkpoint inhibitors block the programmed death-1 receptor and its ligand, cytotoxic T-lymphocyte-associated antigen 4 on tumor cells and lymphocytes, that induces cytotoxic reactions. Nowadays, there are no approved clinical and laboratory predictor markers of immune therapy efficacy, which would allow a more personalized approach to patient selection and treatment. The aim of this review is to analyze possible biomarkers of efficacy for treatment with checkpoint inhibitors according to the pathogenic mechanisms of drug action. The review revealed possible predictive biomarkers, that could be classified to 3 groups: biomarkers of high mutagenic potential of the tumor, biomarkers of high activity of adaptive immunity, biomarkers of low activity of the tumor microenvironment. The determination of the described markers before the start of therapy can be used to formulate a treatment regimen, in which the use of various immunomodulatory drugs, inhibitors of proinflammatory cytokines, angiogenic molecules, and probiotics can be considered.
Subject(s)
Adaptive Immunity/immunology , Biomarkers, Tumor/metabolism , Immunotherapy/methods , Humans , Tumor MicroenvironmentABSTRACT
The antituberculosis measures made have achieved their peak efficiency and, if specific measures to increase the detection rates of patients in the general population and the level of vaccination cannot be found now, tuberculosis morbidity rates cannot be expected to become lower in the near future. This is evidenced by the 1996 prognosis that the morbidity will rise from 84.6 to 96.1 per 10,000 persons. It is expedient to implement preventive antituberculosis measures, by taking into account the regional features of a specific area.